Baseline Characteristics | Fossa-only (n = 77) | WPRT (n = 43) | Difference |
---|---|---|---|
Age at radiation therapy in years | |||
Mean | 66.9 | 66.9 | p = 0.98 |
Standard deviation | 7.5 | 6.5 | |
Initial PSA value in ng/ml | |||
Mean | 18.1 | 18.6 | p = 0.927 |
Standard deviation | 26.8 | 18.0 | |
Gleason score (surgical specimens, No., percentage) | |||
Gleason 6 | 2 (2.6%) | 0 | |
Gleason 7a | 15 (19.5%) | 9 (20.9%) | |
Gleason 7b | 30 (39.0%) | 10 (23.3%) | p = 0.087§ |
Gleason 8 | 7 (9.1%) | 4 (9.3%) | |
Gleason 9 | 22 (28.6%) | 19 (44.2%) | |
Gleason 10 | 1 (1.3%) | 1 (2.3%) | |
Surgical margin (No., percentage) | |||
R0 | 29 (37.7%) | 16 (37.2%) | p = 1.0 |
R1 | 48 (62.3%) | 27 (62.8%) | |
R2 | – | – | |
Dose level (Gy, prescribed dose, EQD-2 to PTV-2) | |||
Lower-dose (71.43 Gy) | 29 (37.7%) | 13 (30.2%) | p = 0.433 |
High-dose (79.29 Gy) | 48 (62.3%) | 30 (69.8%) | |
Time from surgery to radiation therapy (S-RT-Interval in months) | |||
Mean | 13.3 | 6.1 | p = 0.003# |
Median | 5.1 | 3.6 | |
Standard deviation | 18.7 | 6.2 | |
Salvage or postoperative (adjuvant or R1) treatment indication (No., percentage) | |||
Salvage | 41 (53.2%) | 17 (39.5%) | p = 0.184 |
Postoperative | 36 (46.8%) | 26 (60.5%) | |
Roach scores | |||
Mean | 28.9 | 32.8 | p = 0.27 |
Standard deviation | 20.8 | 15.0 | |
Concurrent androgen deprivation therapy (ADT) | |||
Yes | 7 (9.1%) | 6 (14%) | p = 0.541 |
No | 70 (90.9%) | 37 (86%) | |
Pathologically identified number of lymph nodes (all N0) | |||
Mean | 11.0 | 5.9 | p < 0.001† |
Standard deviation | 6.5 | 3.9 | |
≥ 10 nodes identified | 42 (54.5%) | 2 (4.7%) | |
< 10 nodes identified | 35 (45.5%) | 41 (95.3%) | |
Post-surgery PSA at start of radiotherapy (if available) in ng/ml | |||
Mean | 0.73 | 0.71 | p = 0.958 |
Standard deviation | 1.62 | 1.66 | |
Laparoscopic or retropubic surgery | |||
Laparoscopic | 31 (40.3%) | 23 (53.5%) | p = 0.184 |
Retropubic | 46 (59.7%) | 20 (46.5%) |